INT103923

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.53
First Reported 2002
Last Reported 2010
Negated 3
Speculated 0
Reported most in Body
Documents 23
Total Number 23
Disease Relevance 13.95
Pain Relevance 10.64

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Mapk14) cell morphogenesis (Mapk14) response to stress (Mapk14)
cytoplasm (Mapk14) cytosol (Mapk14) nucleus (Mapk14)
Anatomy Link Frequency
spinal 6
endothelial cell 2
liver 2
nerve 2
spinal cord dorsal horn 2
Mapk14 (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 34 100.00 Very High Very High Very High
long-term potentiation 87 99.96 Very High Very High Very High
Neuropathic pain 333 99.80 Very High Very High Very High
Spinal cord 150 99.68 Very High Very High Very High
antagonist 18 99.68 Very High Very High Very High
Pain 131 99.36 Very High Very High Very High
intrathecal 45 99.32 Very High Very High Very High
Dorsal horn 15 99.20 Very High Very High Very High
Painful diabetic neuropathy 54 98.84 Very High Very High Very High
chemokine 30 96.88 Very High Very High Very High
Disease Link Frequency Relevance Heat
Nervous System Injury 200 100.00 Very High Very High Very High
Neuropathic Pain 473 99.80 Very High Very High Very High
Pain 166 99.36 Very High Very High Very High
Diabetic Neuropathy 77 98.84 Very High Very High Very High
Pressure And Volume Under Development 13 97.88 Very High Very High Very High
Targeted Disruption 94 97.64 Very High Very High Very High
Diabetes Mellitus 88 96.72 Very High Very High Very High
Motor Neuron Diseases 42 95.84 Very High Very High Very High
Cancer 134 94.24 High High
INFLAMMATION 244 92.44 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Interestingly, CCR2, one type of receptors for MCP-1, was expressed in spinal microglia; spinal p38 activation after nerve injury is reduced in CCR-2 null mice [27].
Negative_regulation (reduced) of Positive_regulation (activation) of p38 in spinal associated with nervous system injury
1) Confidence 0.53 Published 2007 Journal Mol Pain Section Body Doc Link PMC2186318 Disease Relevance 1.01 Pain Relevance 0.76
Minocycline also inhibits spinal p38 activation in a neuropathic pain condition [40].
Negative_regulation (inhibits) of Positive_regulation (activation) of p38 in spinal associated with neuropathic pain
2) Confidence 0.53 Published 2007 Journal Mol Pain Section Body Doc Link PMC2186318 Disease Relevance 1.44 Pain Relevance 1.30
One caveat to our approach and that of our colleagues is that intrathecal administration of p38 inhibitors prevents p38 activation in both central and peripheral areas of the nervous system, thus the roles of site-specific p38 activation cannot be determined using this approach.
Negative_regulation (prevents) of Positive_regulation (activation) of p38 in nervous system associated with intrathecal
3) Confidence 0.50 Published 2010 Journal Mol Pain Section Body Doc Link PMC2881061 Disease Relevance 0.67 Pain Relevance 0.99
Yohimbine and 2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-2-yl)4,5-dihydro-1H-imidazole (RX821002), alpha(2)-adrenoceptor antagonists, significantly blocked agonist-induced interleukin-12 production and p38 MAPK activation, indicating that the effects of the agonists were mediated through alpha(2)-adrenoceptor.
Negative_regulation (blocked) of Positive_regulation (activation) of p38 MAPK associated with antagonist and agonist
4) Confidence 0.46 Published 2003 Journal Eur. J. Pharmacol. Section Abstract Doc Link 12706479 Disease Relevance 0 Pain Relevance 0.64
Deltorphin-Dvariant did not alter activation of the transcription factors NF-kappaB or AP-1, but greatly reduced activation of p38 MAPK.
Neg (not) Negative_regulation (reduced) of Positive_regulation (activation) of p38
5) Confidence 0.46 Published 2005 Journal J. Surg. Res. Section Body Doc Link 15921696 Disease Relevance 0 Pain Relevance 0
Conversely, a neutralizing antibody against CX3CR1 reduces both p38 activation and neuropathic pain [26].
Negative_regulation (reduces) of Positive_regulation (activation) of p38 associated with neuropathic pain
6) Confidence 0.39 Published 2007 Journal Mol Pain Section Body Doc Link PMC2186318 Disease Relevance 1.37 Pain Relevance 0.96
inhibitor prevents neuropathic pain development by inhibiting spinal p38 activation [36].
Negative_regulation (inhibiting) of Positive_regulation (activation) of p38 in spinal associated with neuropathic pain
7) Confidence 0.39 Published 2007 Journal Mol Pain Section Body Doc Link PMC2186318 Disease Relevance 0.80 Pain Relevance 0.77
However, nerve conduction blockade does not reverse p38 activation when applied after nerve injury [38].
Neg (not) Negative_regulation (reverse) of Neg (not) Positive_regulation (activation) of p38 in nerve associated with nervous system injury
8) Confidence 0.39 Published 2007 Journal Mol Pain Section Body Doc Link PMC2186318 Disease Relevance 0.90 Pain Relevance 0.66
Inhibition of p38 activation prevents the development of PDN in streptozotocin (STZ)-treated animal models of type 1 diabetes [14].
Negative_regulation (Inhibition) of Positive_regulation (activation) of p38 associated with painful diabetic neuropathy and diabetes mellitus
9) Confidence 0.37 Published 2010 Journal Mol Pain Section Body Doc Link PMC2881061 Disease Relevance 1.79 Pain Relevance 1.26
CONCLUSIONS: The data show that delta2- but not delta1-opioid agonists suppress LPS-induced p38 MAPK activation and expression of TNFalpha and MIP-2.


Neg (not) Negative_regulation (suppress) of Positive_regulation (activation) of p38
10) Confidence 0.33 Published 2005 Journal J. Surg. Res. Section Body Doc Link 15921696 Disease Relevance 0 Pain Relevance 0
With respect to the molecular mechanism underlying BV, we observed that BV treatment triggered a reduction in the activation of p38 MAPK, which is downstream of the TNF-?
Negative_regulation (reduction) of Positive_regulation (activation) of p38 MAPK
11) Confidence 0.32 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC2974667 Disease Relevance 0.80 Pain Relevance 0.42
Although the prolonged activation of p38 also was attenuated in ASK1(-/-) mice, the p38 signaling pathway was not likely to be involved in APAP-induced liver injury.
Negative_regulation (attenuated) of Positive_regulation (activation) of p38 in liver
12) Confidence 0.23 Published 2008 Journal Gastroenterology Section Body Doc Link 18700144 Disease Relevance 0.14 Pain Relevance 0
Cross-linking of CD45RB inhibits LPS induced activation of p38 pathway as well as microglial activation
Negative_regulation (inhibits) of Positive_regulation (activation) of p38
13) Confidence 0.20 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2366070 Disease Relevance 0 Pain Relevance 0
This effect was markedly suppressed by CD45RB antibody (2.5 µg/mL), suggesting that cross-linking CD45RB may attenuate activation of p38 MAPK induced by LPS.
Negative_regulation (suppressed) of Positive_regulation (activation) of p38 MAPK
14) Confidence 0.20 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2366070 Disease Relevance 0.15 Pain Relevance 0.07
These mechanisms include: blocking the binding of VEGF121 and VEGF165 to the KDR/Flk-1 receptor, which mediates endothelial cell motility and proliferation; blocking phosphorylation of the tyrosine receptor; and blocking activation of the intracellular signaling kinases ERK, p38 MAPK, and p125 FAK [34,35].
Negative_regulation (blocking) of Positive_regulation (activation) of p38 MAPK in endothelial cell
15) Confidence 0.18 Published 2010 Journal BMC Med Section Body Doc Link PMC2989928 Disease Relevance 1.16 Pain Relevance 0.04
The i.pl. injection of PGE2 (3 nmol/paw) induced a significant activation of MAPKs, namely, JNK and p38, an effect that was largely prevented by the selective EP3 receptor antagonist L826266 (10 nmol/paw).
Negative_regulation (prevented) of Positive_regulation (induced) of p38 in PGE2 associated with antagonist
16) Confidence 0.17 Published 2006 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 16644903 Disease Relevance 0.39 Pain Relevance 0.48
induced activation of p38 MAPK to impair LTP.44 On the other hand, A?
Negative_regulation (impair) of Positive_regulation (activation) of p38 MAPK associated with long-term potentiation
17) Confidence 0.12 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2938309 Disease Relevance 0.39 Pain Relevance 0.29
In addition, R-flurbiprofen significantly reduced the activation of p38 MAP kinase in the spinal cord dorsal horn as revealed by quantitative phospho-p38 analysis (Fig. 7 b, c).
Negative_regulation (reduced) of Positive_regulation (activation) of p38 MAP kinase in spinal cord dorsal horn associated with dorsal horn and spinal cord
18) Confidence 0.12 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2869361 Disease Relevance 0.27 Pain Relevance 0.40
Since activation of p38 mitogen-activated protein kinase (p38 MAPK) phosphorylation is decreased by antibodies against RAGE, suppression of LTP inhibition has been achieved by blocking p38 MAPK.
Negative_regulation (decreased) of Positive_regulation (activation) of p38 associated with long-term potentiation
19) Confidence 0.12 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2938309 Disease Relevance 0.44 Pain Relevance 0.38
Since activation of p38 mitogen-activated protein kinase (p38 MAPK) phosphorylation is decreased by antibodies against RAGE, suppression of LTP inhibition has been achieved by blocking p38 MAPK.
Negative_regulation (decreased) of Positive_regulation (activation) of p38 MAPK associated with long-term potentiation
20) Confidence 0.12 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2938309 Disease Relevance 0.44 Pain Relevance 0.38

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox